Pregnancy safety check for rare disease drug

NCT ID NCT05040373

Recruiting now Knowledge-focused Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 24 times

Summary

This study monitors women who were exposed to the drug patisiran during pregnancy to see how their pregnancies and babies turn out. It aims to identify any birth defects or complications. About 10 participants will be followed, and no new treatments are being tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Iowa City, Iowa, 52242, United States
Clinical Trial Site
RECRUITING

Nantes, France
Clinical Trial Site
RECRUITING

Münster, Germany
Clinical Trial Site
RECRUITING

Pavia, Italy
Clinical Trial Site
RECRUITING

Groningen, Netherlands
Clinical Trial Site
RECRUITING

Lisbon, Portugal
Clinical Trial Site
RECRUITING

Madrid, Spain

Conditions

Explore the condition pages connected to this study.

HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS POLYNEUROPATHY